Hi Elaine,

MOE can write *.mol2 files. I used one of those. I could not use viewdockx on that model.

Wonder what was missing in that file…..

 

 

-----Original Message-----
From: Elaine Meng <meng@cgl.ucsf.edu>
Sent: Thursday, March 28, 2024 3:37 PM
To: Krishnan Raman <RKrishnan@BIOCRYST.com>
Cc: chimerax-users@cgl.ucsf.edu
Subject: Re: [chimerax-users] *.mdb files from MOE (chemcomp)

 

[EXTERNAL]

 

Hello Krish,

It all depends on what format the MOE docking results are, or can optionally be written, in. Further, not all formats that ChimeraX can read and display as atomic coordinates are interpreted specifically as docking results that will be listed in and interact properly with the ViewDockX interface.  Some formats are merely shown as atomic structures but do not "talk" to ViewDockX because they don't have the specific score records expected for a specific format.

 

For a list of the atomic formats that ChimeraX reads, see:

<https://link.edgepilot.com/s/cee5f41f/3qU0LsnJYE6FzcLQpoC5qA?u=https://rbvi.ucsf.edu/chimerax/docs/user/commands/open.html%23atomic>

 

For a list of the types of docking results recognized as such by the ChimeraX ViewDockX, see:

<https://link.edgepilot.com/s/18baa070/AzeY3IWbekutdI3S9h4WzQ?u=https://rbvi.ucsf.edu/chimerax/docs/user/tools/viewdockx.html>

 

So if the above are not included amongst the MOE output options, you would have to develop a format conversion process to generate one of them.

 

I hope this helps,

Elaine

-----

Elaine C. Meng, Ph.D.

UCSF Chimera(X) team

Department of Pharmaceutical Chemistry

University of California, San Francisco

 

> On Mar 28, 2024, at 12:22 PM, Krishnan Raman via ChimeraX-users <chimerax-users@cgl.ucsf.edu> wrote:

> 

> how to convert docking poses from MOE software to be read into chimerax?

> thanks

> Krish

> CONFIDENTIALITY NOTICE This email, including any attachments, may contain confidential or legally privileged information that is intended only for the individual or entity to whom it is addressed. If you are not the intended recipient, please be advised that any dissemination, distribution or copying of this email and any attachment is strictly prohibited. If you have received this email in error, please reply to the sender so that BioCryst Pharmaceuticals, Inc. can take corrective measures and then permanently delete this email and any attachment, including any printed copies. Thank you.

 

 

 

Links contained in this email have been replaced. If you click on a link in the email above, the link will be analyzed for known threats. If a known threat is found, you will not be able to proceed to the destination. If suspicious content is detected, you will see a warning.

CONFIDENTIALITY NOTICE

This email, including any attachments, may contain confidential or legally privileged information that is intended only for the individual or entity to whom it is addressed. If you are not the intended recipient, please be advised that any dissemination, distribution or copying of this email and any attachment is strictly prohibited. If you have received this email in error, please reply to the sender so that BioCryst Pharmaceuticals, Inc. can take corrective measures and then permanently delete this email and any attachment, including any printed copies. Thank you.